GlobeNewswire Inc.··Johnson & JohnsonJ&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma
Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial